Cyclenium Pharma Initiates Laboratory Operations at the NEOMED Institute

MONTREAL AND SHERBROOKE, QC, March 28, 2014 /CNW Telbec/ - Cyclenium Pharma Inc., a newly formed pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the opening of its laboratories at the NEOMED Institute in Montreal, Canada.

Founded by management and scientists from the pioneering macrocyclic drug discovery and development company, Tranzyme Pharma, which recently closed its Sherbrooke R & D site, Cyclenium is capitalizing on fifteen years of experience and expertise in macrocycle chemistry and targeting creation of a second generation technology that addresses the limitations of the initial efforts in this field.

"We are very pleased with this opportunity to jump start our R & D efforts at the NEOMED Institute," said Dr. Helmut Thomas, President and CEO of Cyclenium Pharma. "The location is ideal in providing a host of services that would otherwise be beyond the reach of a start-up enterprise. This will permit us to concentrate our attention on rapidly building our capabilities and developing our breakthrough next generation macrocyclic library."

The NEOMED Institute is a dedicated center of excellence for drug R&D. It offers a high quality environment with access to highly specialized equipment. It also encourages synergies between resident companies leading to collaborative projects. Since its inception in November 2012, the Institute is now host to 17 life sciences companies.

"We are delighted to welcome Cyclenium Pharma into the NEOMED Institute and are confident that its research work in macrocycle chemistry will be successful," said Max Fehlmann, President and CEO of the NEOMED Institute. "Cyclenium is the type of innovative company we seek to nurture and is a strong addition to our roster of resident companies."

About Cyclenium Pharma
Cyclenium Pharma is an emerging pharmaceutical research and development company pursuing development of selected product opportunities in areas of unsatisfied medical need, while simultaneously creating a second generation macrocyclic drug discovery technology. Cyclenium is building value through progression of our internal programs and establishing collaborations with innovative pharmaceutical and biotechnology companies seeking to modulate difficult disease targets. For more on Cyclenium Pharma, please see: www.cyclenium.com.

About the NEOMED Institute
The NEOMED Institute is a state-of-the-art R&D facility in the Montreal Technoparc. The Institute acts as an open-access drug discovery hub hosting drug discovery and development research companies, providing a unique environment to foster innovation, collaboration and creativity. For more information, please visit: www.neomed.ca

SOURCE Cyclenium Pharma Inc.

For further information:

Helmut Thomas, Ph.D.
President & CEO
Cyclenium Pharma Inc.
Telephone: + 1 514-745-1439
hthomas@cyclenium.com

Mounia Azzi, Ph.D.
Director of Scientific Affairs
The NEOMED Institute (Canada)
Telephone: +1 514-267-1212, ext. 202
mazzi@neomed.ca